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ABSTRACT: Alpha-synuclein (a-Syn) aggregates
are the main component of Lewy bodies, which are the
characteristic pathological feature in Parkinson’s disease
(PD) brain. Evidence that a-Syn aggregation can be
propagated between neurones has led to the suggestion
that this mechanism is responsible for the stepwise pro-
gression of PD pathology. Decreasing a-Syn expression
is predicted to attenuate this process and is thus an
attractive approach to delay or halt PD progression. We
have used a-Syn small interfering RNA (siRNA) to
reduce total and aggregated a-Syn levels in mouse
brains. To achieve widespread delivery of siRNAs to the
brain we have peripherally injected modified exosomes
expressing Ravies virus glycoprotein loaded with siRNA.
Normal mice were analyzed 3 or 7 days after injection.
To evaluate whether this approach can decrease a-Syn
aggregates, we repeated the treatment using transgenic
mice expressing the human phosphorylation-mimic
S129D a-Syn, which exhibits aggregation. In normal
mice we detected significantly reduced a-Syn messen-
ger RNA (mRNA) and protein levels throughout the brain
3 and 7 days after treatment with RVG-exosomes
loaded with siRNA to a-Syn. In S129D a-Syn transgenic
mice we found a decreased a-Syn mRNA and protein
levels throughout the brain 7 days after injection. This
resulted in significant reductions in intraneuronal protein
aggregates, including in dopaminergic neurones of the
substantia nigra. This study highlights the therapeutic
potential of RVG-exosome delivery of siRNA to delay
and reverse brain a-Syn pathological conditions. VC 2014
The Authors. Movement Disorders published by Wiley
Periodicals, Inc. on behalf of International Parkinson and
Movement Disorder Society.
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INTRODUCTION
Combined with the ubiquitous presence of alpha-
synuclein (a-Syn) aggregates in Lewy bodies (LBs), the
finding of mutations in and multiplications of the a-Syn
gene in familial Parkinson’s disease (PD) all point to the
central role of a-Syn in PD pathogenesis.1 In 2003, Braak
and colleagues2 described the staging of PD pathology
based on the progression of a-Syn pathology from the
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brainstem to the cortex, consistent with the pathological
propagation along specific neural pathways,2 although
this is not a feature observed in all PD patients.3 Given
the central role of a-Syn in PD pathology, strategies to
decrease the expression of a-Syn in neurons are attractive
approaches to delay PD progression. Although gene ther-
apy is a powerful tool to down-regulate the expression of
a-Syn,4 one of the major challenges for clinical applica-
tion is the development of a safe and efficient vehicle to
deliver the therapy to the brain. The brain is a particularly
difficult target for drugs of all classes because the blood–
brain barrier excludes most drugs with a size greater than
400 Da.5 Furthermore, delivery of the therapy through-
out the brain is required because of the widespread nature
of the a-Syn pathology in PD. Gene therapy approaches
used in clinical trials have involved local delivery of viral
vectors containing complementary DNA (cDNA) encod-
ing for a specific protein.6 However, these are limited by
the requirement for stereotactic surgery and delivery
restricted to a limited anatomically defined brain region.
Although transvascular gene therapy using liposomes has
been used in animal models,7 immune activation mediates
the rapid clearance of the vehicle and concomitant
decrease in efficacy when liposomes are re-administered,
limiting the duration of the therapy. To overcome these
limitations, we have developed a system that uses sys-
temic administration of modified exosomes for nucleic
acid delivery to the brain.8
Exosomes are extracellular vesicles (40-120 nm) of
endocytic origin released by numerous cell types that act
as natural carriers of messenger RNA (mRNA), micro-
RNA, and proteins between cells.9 We have previously
developed modified exosomes that specifically target the
brain by expressing a brain-targeting peptide (rabies virus
glycoprotein peptide; RVG) in the extra-exosomal N-ter-
minus of Lamp2b, a protein found abundantly in the
membrane of exosomes derived from primary dendritic
cells. Previously we demonstrated that intravenous injec-
tion of RVG-exosomes containing small interfering RNA
(siRNAs) into normal mice led to the targeted silencing
of Beta-secretase 1 or glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) expression in the brain highlighting
its potential therapeutic value for neurological diseases8.
To evaluate the potential of this approach for PD
treatment we have assessed the ability of RVG-
exosomes loaded with siRNA-targeted for a-Syn to
decrease a-Syn and its aggregates in the brains of
mice.
Methods
Cell Culture and Exosome Purification
Murine dendritic cells harvested from bone marrow
were cultured in complete medium.8 Cells were trans-
fected after 4 days with 5 mg RVG-Lamp2b plasmid
and 5 mL of TransIT LT1 transfection reagent (Mirus
Bio). Cell culture medium was changed on day 7, cell
culture supernatant harvested after 24 hours, and exo-
somes isolated by serial centrifugation. Exosomes were
resuspended in 0.1 M ammonium acetate.
Exosome Treatment of Mice
All the experiments were approved by the Swedish
Local Board for Laboratory Animals and the UK
Home Office. Twelve- to 14-week-old normal C57BL/
6 mice and 20- to 22-week-old C57BL/6 transgenic
mice expressing the human S129D a-Syn cDNA under
the PrP promoter were used for experiments. One
hundred fifty micrograms of a-Syn siRNA was electro-
porated into 150 mg siRNA RVG-exosomes, centri-
fuged and resuspended in 80 mL of 5% glucose
immediately before tail vein injection. Animals were
analyzed 3 or 7 days after injection.
Alpha-Synuclein Analysis
Alpha-synuclein protein differential solubility and
total levels were analyzed by western blotting.10
Alpha-synuclein mRNA levels were analyzed by quan-
titative polymerase chain reaction (qPCR).10 Presence
of a-Syn aggregates was analyzed by ThioS and immu-
nohistochemical staining.11
Detailed methods and statistical analyses can be
found in the Supplementary Data.
RESULTS
In Vitro Validation of siRNAs Against Alpha-
Synuclein
Three different siRNA sequences (siRNA1, 2, and 3)
were designed to the coding sequence common to
mouse and human a-Syn (Supplemental Data Table 1)
to down-regulate their expression without targeting
beta or gamma-synuclein (Supplemental Data Table
2). The ability of these siRNAs to knock down wild-
type mouse a-Syn was assessed in human SH-SY5Y
cells expressing mouse a-Syn-HA (mSyn-SHSY5Y).
Using conventional lipofection reagents, we demon-
strated a decrease in the total a-Syn mRNA in cells
treated with each of the three siRNAs relative to con-
trols (13%, 45%, and 55% decrease, respectively),
although this was only statistically significant for
siRNA2 and siRNA3 (Fig. 1A). The decrease in
ectopic mouse a-Syn protein level was greater than the
decrease in mRNA levels; significant decreases were
obtained with all three siRNAs (45%, 70%, and 80%
decrease, respectively) (Fig. 1B). The experiments were
repeated using RVG-exosomes to deliver the siRNAs
to the cells. RVG-exosomes were loaded with the
three different siRNAs and added to the mSyn-
SHSY5Y cell culture medium. After 72 hours, all three
siRNAs delivered by RVG-exosomes reduced total a-
Syn mRNA (55%, 65%, and 80% decrease,
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respectively), and protein (64%, 68%, and 85%
decrease, respectively) levels (Fig. 1C, D). Small inter-
fering RNA3 was selected as the most efficient
sequence. These results validated the use of RVG-
exosomes for siRNA delivery and suggested a higher
efficiency of RVG-exosomes than a conventional lipo-
fection agent (Supplemental Data Fig. 1).Thus, we
next set out to investigate the feasibility of this
approach to silence a-Syn in vivo.
Down-Regulation of Endogenous Alpha-
Synuclein in Normal Mouse Brain
The homogeneity of the RVG-exosomes used in this
study was confirmed by nanoparticle tracking analysis
demonstrating homogenous populations of exosomes
with a size distribution peaking at a diameter around
100 nm (Supplemental Data Fig. 2). To investigate the
brain distribution of RVG-exosomes after systemic
delivery, RVG-exosomes labeled with a lipophilic
IRDye (DiR) were injected intravenously into normal
mice. After 24 hours the brains from mice treated
with RVG-exosomes demonstrated a significant (3.8-
fold) increase in fluorescence (p< 0.01) compared
with untreated controls (Supplemental Data Fig. 2),
which was throughout the brain, demonstrating a
widespread distribution of RVG-exosomes.
To examine the in vivo efficacy of siRNA3 RVG-
exosomes to down-regulate endogenous a-Syn in the
brain, RVG-exosomes loaded with siRNA3 were
injected intravenously into normal mice. Brains were
dissected 3 and 7 days after injection and analyzed for
a-Syn mRNA and protein levels. After 3 days there
were significant decreases in a-Syn mRNA levels in
midbrain, striatum, and cortex samples (50%, 45%,
and 55% decrease, respectively), with a concomitant
decrease in a-Syn protein levels (45%, 43%, and 24%
decrease, respectively) compared with untreated control
mice (Fig. 2A, B). These decreases were similar 7 days
post-injection, with mRNA levels in the midbrain,
FIG. 1. Analysis of a-Syn knockdown by various siRNAs in cell models. SH-SY5Y cells over-expressing mouse a-Syn-HA were treated with 100 nM
of three different siRNAs (siRNA 1, 2, or 3) using Hiperfect transfection reagent (A, B) or 3 lg RVG exosomes loaded with the different siRNAs (C, D).
After 3 days, total a-Syn mRNA levels were quantified by qPCR relative to GAPDH (A, C) and mouse a-Syn (anti-HA antibody) protein levels relative to
actin by Western blot (B, D). Data expressed as mean6SEM (n54). Statistical analyses compared with control group, *p< 0.05, **< 0.01, ***< 0.001.
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striatum, and cortex decreased by 47%, 59%, and
52%, respectively, and a-Syn protein levels decreased
by 44%, 38%, and 22%, respectively (Fig. 2C, D).
These results confirmed the in vivo potential for the sys-
temic delivery of siRNAs by RVG-exosomes to decrease
the expression of a-Syn in brain regions relevant to PD.
Down-Regulation of Human Phospho-Mimic
S129D Alpha-Synuclein in Transgenic Mouse
We have generated a transgenic (Tg) mouse model
expressing the phospho-mimic human S129D a-Syn
cDNA with a C-terminal HA tag under the control of the
PrP promoter. This model (PrP-hSNCA-HAS129D line 13;
FIG. 2. The effect of intravenous injection of siRNA3 RVG-exosomes on brain a-Syn levels in normal mice. Normal mice were injected intrave-
nously with siRNA3 RVG exosomes (150 lg) and the brain removed and dissected 3 days (A, B) and 7 days (C, D) after injection. Alpha-synuclein
mRNA levels were analyzed by qPCR relative to GAPDH (A, C), and protein levels analyzed by Western blot relative to actin (B, D), in the midbrain
(MB), striatum (Str), and cortex (Ctx). Typical Western blots showing a-Syn and actin blots for midbrain, striatum, and cortex samples from control
and siRNA RVG-exosome treated mice are shown (B, D). Data normalized to control levels and expressed as mean6SEM (n58). Statistical analy-
ses compared with untreated control group, *p< 0.05, ** p< 0.01.
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FIG. 3. Characterisation of the features of the human S129D a-Syn transgenic mouse Tg13. (A) Immunohistochemical detection with DAB
(brown staining) of S129D a-Syn HA expression using an anti-HA antibody in 6-month-old control (left panel) and Tg (right panel) mice. (B) Western
blot analyses of whole tissue extract (upper panel) or sequential extractions with high salt (HS), Triton X-100, and urea/SDS (Urea) (lower panel) for
cortex (Ctx), hippocampus (Hip), midbrain (MB), striatum (Str), brain stem (BS), cerebellum (Cbl), olfactory lobe (OL), and cord, using anti-HA or anti-
actin antibodies. (C) Western blot analysis of whole midbrain extracts (Total) and triton X-100 insoluble material (urea) from Tg13 mice of different
ages (1.5-24 months). Graph represents changes in total a-Syn relative to actin and changes in triton insoluble urea soluble a-Syn, data normalized
to the values at 1.5 months. (D) Magnification of the anti-HA immunohistochemistry with DAB detection of the thalamus region of a Tg13 mouse at
5 months of age demonstrating cytoplasmic DAB-positive inclusions (arrows). (E) Western blot comparison of a-Syn expression in the midbrain and
striatum of control and Tg13 (S129D) mice relative to actin, data normalized to the control values. [Color figure can be viewed in the online issue,
which is available at wileyonlinelibrary.com.]
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referred to as Tg13 below) demonstrates a-Syn expres-
sion throughout the brain (Fig. 3A, B). Triton X-100
insoluble a-Syn was evident from as young as 6 weeks of
age and increased with age in all regions tested (midbrain
shown Fig. 3C). Although all regions exhibited evidence
of triton X-100 insoluble a-Syn, it appeared more promi-
nent in the cortex, cerebellum, and striatum (Fig. 3B),
consistent with increased aggregation associated with
S129 phosphorylated a-Syn in LBs in PD.12 This is con-
sistent with the immunohistochemical HA-positive cyto-
plasmic inclusions that were observed throughout the
brain from 3 months of age (Fig. 3D). The level of S129D
a-Syn expression relative to endogenous mouse expres-
sion was increased by between 3 to 5 times (Fig. 3E).
However, the analysis of activity13 and motor skills13 at 6
months of age, or dopamine levels at 9 months, did not
reveal any abnormality (Supplemental Data Fig. 3).
Increased a-Syn aggregation is a characteristic patho-
logical feature of PD in many brain regions; therefore, it
is important to determine whether systemically delivered
siRNA RVG-exosomes can influence a-Syn pathology in
these regions. To confirm that siRNA3 is effective at
decreasing the expression of human S129D a-Syn, we
treated SH-SY5Y cells overexpressing human S129D a-
Syn-HA with different concentrations of siRNA-RVG
exosomes. There was a clear dose-dependent decrease in
S129D a-Syn-HA protein relative to actin (Fig. 4A), con-
firming that siRNA3 RVG-exosomes can effectively
down-regulate human S129D a-Syn.
Tg13 mice were injected intravenously with RVG-
exosomes loaded with siRNA3 at 5 months of age or
left untreated. After 7 days, a-Syn-HA mRNA and pro-
tein levels were analyzed in three and eight different dis-
sected brain regions, respectively. The mRNA levels
were significantly decreased in the three brain regions
most relevant to PD; midbrain (49% decrease), striatum
(56% decrease), and cortex (50% decrease) (Fig. 4B).
This was paralleled by a significant decrease in S129D
a-Syn-HA protein levels in the midbrain (32%
decrease), striatum (26% decrease), and cortex (30%
decrease), although the decrease was slightly less
marked than that seen for the mRNA (Fig. 3B). Mean
S129D a-Syn-HA protein levels were also down-
regulated in the other five regions analyzed, this was sig-
nificant for the cerebellum (decreased 45%), brain stem
(decreased 29%), thalamus (decreased 44%), and spinal
cord (decreased 30%), although these did not reach sta-
tistical significance for the olfactory lobe (decreased
16%) (Supplemental Data Fig. 4A, B).
To confirm the specificity of the down-regulation,
we tested a chemically modified siRNA sequence (con-
trol, CsiRNA) that differed from siRNA3 in one
nucleotide (Supplemental Data Table 1). This control
siRNA (CsiRNA) did not induce a-Syn down-regula-
tion at mRNA (Supplemental Data Fig. 5A) or protein
levels (Supplemantal Data Fig. 5B) in cell cultures. A
new batch of Tg13 mice were injected with RVG-
exosomes loaded with CsiRNA or left untreated. After
7 days there was no difference in a-Syn-HA mRNA or
protein levels between CsiRNA RVG-exosome and
untreated groups for the three brain regions tested
(Fig. 4C), confirming the role of the siRNA3 in the a-
Syn down-regulation observed with the RVG-exosome
treatment.
To examine the influence of a-Syn down-regulation on
a-Syn aggregation in the transgenic mice, midbrain sec-
tions were stained with the green fluorescent dye Thiofla-
vin S (ThioS), which stains amyloid deposits. Untreated
Tg13 midbrain sections demonstrated widespread cyto-
plasmic ThioS positivity (Fig. 5A, arrows); this is consist-
ent with the presence of a-Syn aggregates and the increase
in triton insoluble a-Syn in the brains of these mice (Fig.
3B). ThioS staining of the midbrain sections from the
mice was greatly diminished 7 days after siRNA3 RVG-
exosome treatment (Fig. 5A), with staining decreased by
84% (ImageJ quantification) relative to untreated samples
(Fig. 5A). In midbrain samples from untreated mice, most
of the S129D a-Syn was extracted in the high salt and tri-
ton fractions with a small proportion in the sodium
dodecyl sulfate (SDS}/urea fraction corresponding to insol-
uble aggregated protein (Fig. 5B). After treatment of Tg13
mice with siRNA3 RVG-exosomes sequential extraction
of midbrain samples showed a decrease in a-Syn levels in
all 3 fractions with slightly greater reductions in the
membrane-associated (Triton X-100) and insoluble (SDS/
urea) fractions (Fig. 5B), consistent with a decrease in
both the soluble and aggregated forms of the protein.
Finally, we assessed the immunohistochemical distribu-
tion of S129D a-Syn-HA in the pathologically relevant
dopaminergic neurones in the substantia nigra pars com-
pacta. In untreated transgenic mice a-Syn-HA puncta can
be seen in tyrosine hydroxylase–positive neurones (Fig.
5C, arrow), which were decreased in the mice 7 days after
injection with siRNAs RVG-exosomes (Fig. 5D, Supple-
mental Data Fig. 5C)
Discussion
Although effective symptomatic treatments for PD
are available and patient management has improved
dramatically in recent years, PD is inexorably progres-
sive, and there is currently no disease-modifying
therapy.
Whereas the mechanisms underlying the clinical and
pathological features of PD remain to be defined, a-
Syn clearly plays a central role in the disease process
with elevated a-Syn levels apparently sufficient to lead
to some familial forms of PD.14,15 This suggests that
the down-regulation of a-Syn is an attractive strategy
to delay disease progression, even though it is not
clear whether oligomers, protofibrils, or larger aggre-
gates are the pathological form of the protein.12,16 A
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previous study demonstrated that infusion of modified
siRNA against a-Syn into the hippocampus of normal
mice down-regulated a-Syn in the hippocampus over
14 days.4 However, the highly invasive nature of the
delivery method used and the confined distribution of
the siRNA renders this approach to siRNA delivery
unsuitable for therapy for diseases such as PD. In con-
trast, RVG-modified exosomes administered by
peripheral intravenous injection are able to deliver
siRNAs into central nervous system neurons,8 suggest-
ing that siRNA knockdown of brain a-Syn may be
practicable by this approach. Toward this end, we
have optimized the siRNAs targeting of both mouse
and human a-Syn to evaluate silencing of endogenous
and ectopic expression in cell cultures.
The localization of RVG-exosomes labeled with the
lipophilic IRDye to the mouse brain within 24h of
intravenous injection confirmed the ability of these
modified exosomes to distribute throughout the brain.
This adds to our previous observation that fluorescent
tagged siRNAs in RVG-exosomes were found in the
brain, and GAPDH and BACE-1 levels were decreased
in several brain regions after the injection of the
appropriate siRNA-loaded RVG-exosomes.8 Using the
FIG. 4. Down-regulation of human S129D a-Syn in SHSY5Y cells and Tg13 mice using siRNA3 RVG-exosomes. (A) Western blot analysis of a-
Syn-HA levels relative to actin 3 days after the addition of increasing amounts of siRNA3-RVG exosomes (0.75-9 mg exosome protein) to SH-SY5Y
cells expressing human S129D a-Syn-HA; lower numbers represent a-Syn protein level relative to actin. (B) qPCR and Western blot analyses of
human S129D a-Syn-HA expression in various brain regions from Tg13 mice (5 months of age) 7 days after intravenous injection with 150 lg
siRNA3 RVG-exosomes (siRNA3), and compared with untreated controls (con). Mid brain (MB), striatum (Str), and cortex (Ctx) samples analyzed for
S129D a-Syn-HA mRNA levels (PCR siRNA3) were expressed relative to GAPDH mRNA and S129D a-Syn-HA protein levels (anti-HA antibody)
expressed relative to actin levels (WB siRNA3). Data were normalized to brain regions from matched controls (PCR control, WB control). Typical
blots of the midbrain, striatum, and cortex samples are shown. Data expressed as mean6SEM (n5 8). Statistical analyses compared with control
group, *p< 0.05, **p< 0.01. (C) As a control, Tg13 mice were injected with 150 lg CsiRNA RVG-exosomes (loaded with the control siRNA) and com-
pared with untreated controls (control). Seven days after injection, brains were dissected (n58 per region) and analyzed as described in section B.
A Western blot of the midbrain samples is shown.
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FIG. 5. Assessment of a-Syn aggregates in Tg13 mice. The influence of siRNA3 RVG-exosome treatment on a-Syn aggregates were assessed
by (A) ThioS staining of aggregates in the mid brain of untreated and siRNA3 RVG-exosome treated Tg13 mice. ThioS-positive inclusions were
clearly observed in the untreated mice (arrows); the ThioS staining was markedly decreased in the siRNA3 RVG-exosomes injected mice (siRNA3-
Exo) brains. The ThioS staining intensity was quantified using Image J (20 neurones analyzed per animal). (B) Sequential extraction of mid brain
samples (3 mg) with high salt (HS), HS/Triton X-100 (Triton), and SDS/urea (urea). The gel was loaded with 5%, 5%, and 20% of each extract,
respectively, and the blot probed with an anti-HA antibody. Data are expressed as mean6SEM. Statistical analyses compared with control group,
*p< 0.05, ***p< 0.001. Immunofluorescent analysis of midbrain sections from untreated (C) or siRNA3 RVG-exosome injected (D) mice using anti-
bodies to S129D a-Syn-HA (red, anti-HA) and tyrosine hydroxylase (green). [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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same in vivo treatment strategy, we have now demon-
strated that injection of a-Syn siRNA3 loaded RVG-
exosomes caused a significant decrease in murine a-Syn
mRNA and protein levels in the brain regions analyzed.
The levels of down-regulation of both a-Syn mRNA and
protein were similar 3 and 7 days after injection and com-
parable in both the midbrain and striatum, and consistent
with our previous data targeting GAPDH.8 It is unclear
why cortical a-Syn protein levels did not decrease as
much despite similar knockdown of the mRNA levels
with the other regions, this had not been observed with
GAPDH knockdown and may indicate that cortical a-
Syn may have a slower turnover than in other regions.
Over this short period the mice did not demonstrate any
clear clinical abnormality which is in keeping with a-Syn
knock-out mice, which are relatively normal, although
knockout mice presented with altered dopamine release
and striatal dopamine reduction.17 Although the RVG-
exosome-siRNA therapy does not lead to a complete loss
of a-Syn, prolonged depletion in adulthood may be func-
tionally more dramatic, so it will be important for future
studies to perform detailed clinical evaluations in mice
with prolonged a-Syn down-regulation.
Lewy bodies are a key pathological feature of the
disease and contain large amounts of a-Syn aggre-
gates, and although their role in the disease mecha-
nisms is not clear, the injection of preformed a-Syn
fibrils18 or human LB19 can propagate some of the
pathological features in mice. Consequently we needed
to determine whether siRNA-loaded RVG-exosomal
therapy can impact on the level of a-Syn aggregates.
Alpha-synuclein aggregates are not a common feature
of transgenic mouse models overexpressing a-Syn.20
However, a-Syn in Lewy bodies is highly phosphoryl-
ated at serine 12921 and S129 phosphorylated a-Syn is
more prone to aggregate.21 Consequently we have
generated a mouse model based on the overexpression
of the human phospho-mimic S129D a-Syn under the
PrP promoter. In this model a-Syn aggregates were
apparent throughout the brain from 3 months of age,
including in TH-positive neurons of the substantia
nigra. This is in keeping with the expression of S129D
a-Syn by Adeno-associated virus in mouse brains,22
which pointed to S129 phosphorylation as an impor-
tant factor in a-Syn deposition in cellular inclusions.23
As a proof of principle, we treated 5-month-old
human S129D a-Syn transgenic mice with siRNA3
loaded RG-exosomes to identify whether the treatment
had any impact on the a-Syn aggregates seen in these
mice. Our results confirmed that systemic siRNA RVG-
exosome treatment decreased the total levels of human
S129D a-Syn protein throughout the brain, including
the midbrain, cortex, and striatum, which are important
areas affected by a-Syn deposition at different stages of
PD pathology. This was not observed using a modified
siRNA sequence, demonstrating that the down-
regulation observed in the treated mice was attributable
to the efficient intracellular delivery of the active siRNA.
Comparison between the siRNA3 RVG-exosome treat-
ments of normal mice with the S129D transgenic mice
revealed a similar reduction in the a-Syn mRNA levels
relative to their respective untreated controls but slightly
less effective in decreasing the S129D a-Syn protein lev-
els. Although this may relate to the higher total a-Syn
levels in the transgenic mice, it is more likely to reflect
the presence of aggregated protein, which may be more
inert and require longer gene down-regulation to have a
greater impact. It is particularly notable that the differ-
ential solubility of a-Syn indicated that both soluble and
aggregated a-Syn was decreased by the therapy but
there remained some triton-insoluble a-Syn after 7 days’
therapy. The decrease in a-Syn aggregates was further
supported by the loss of thioflavin S-positivity in the
midbrain after the therapy. The dynamics of intra-
cellular a-Syn aggregates are not known. However,
there is evidence from several mouse models of Hun-
tington’s disease that the level of huntingtin aggregates
decrease within days of the levels of huntingtin protein
being decreased either by turning off expression24 or by
using siRNA to decrease expression.25 This suggests
that in transgenic mouse models at least htt aggregates
are not fixed but are being generated and either
degraded or dispersed and that a decrease in htt levels is
sufficient to decrease the aggregate levels. Our data sug-
gest this is also true for a-Syn aggregates.
In conclusion, using systemic administration of siR-
NAs, we have been able to significantly decrease the
level of endogenous mouse a-Syn, and a pro-
aggregating human form of a-Syn in a transgenic mouse
model, in brain regions pathologically affected in Par-
kinson’s disease. This is the first time this specific
approach has been used successfully in vivo to decrease
the level of a human protein and more specifically show
a decrease in the level of aggregated protein. These
results reinforce the idea that this approach can be fur-
ther developed to abrogate the disease progression in
PD. Consequently it paves the way for this technology
to be further developed for clinical trials for PD and
opens a new avenue for treatment of a wide variety of
neurological diseases, including Alzheimer’s disease,
Huntington’s disease, and prion disease.
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